TransThera Bioscience, a Nanjing Startup, Raises $10 Million from Morningside

TransThera Biosciences, a Nanjing biotech startup, raised $10 million in an A Round financing that was led by Morningside Ventures of Hong Kong. TransThera is built on an open innovation model that seeks to develop novel NCE drugs. Its current portfolio addresses oncology, cardiovascular diseases and other therapeutic areas. The company was founded (and is led) by Dr. Frank Wu, who was previously CEO of XuanZhu Pharma, a drug discovery subsidiary of Sihuan Pharma. More details.... Share this with colleagues: // //